Compare Southern Copper Corp (SCCO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Southern Copper Corp trades at $197 (market cap $169.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Southern Copper Corp is far larger — about 23.1× Spyre Therapeutics Inc. Common Stock's market cap, and Southern Copper Corp pays a 2.19% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 62 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SCCO | SYRE | |
|---|---|---|
Market Cap | $169.44B | $7.35B |
Volume | 888,492 | 1,624,631 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $108.92 |
52-Week Low | $120.02 | $22.18 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $170.74B | $6.35B |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $207.42, down 0.61% on the day, with strong fundamental performance including 35.9% net margins and 50.1% ROE. The stock shows bullish technical signals with support at $207 and resistance at $210, while consistently beating earnings estimates in recent quarters. Revenue growth accelerated to $13.4B in 2025 with net income reaching $4.3B, supported by operational cash flow of $4.8B.
Despite premium valuations (P/E 31.1, P/S 11.2), SCCO's world-class assets and $10.2B Mexican project pipeline support long-term growth. However, analyst consensus remains cautious with only 10% buy ratings and a $165.60 price target, 20% below current levels. Key risks include copper price volatility and the stock's valuation premium relative to peers.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
